Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N(2024) Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R ESMO Open, 9(6), 103464 DOI 10.1016/j.esmoop.2024.103464, PubMed 38833971
Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å(2024) UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial Eur J Cancer, 202, 113973 DOI 10.1016/j.ejca.2024.113973, PubMed 38447379
Gullhaug A, Haakensen VD, De Ruysscher D, Simone CB, Hotca-Cho AE, Chhabra AM, Hellebust TP, Paulsen EE, Dimopoulos MP, Johansen S(2024) Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes J Med Imaging Radiat Sci, 55(2), 221-231 DOI 10.1016/j.jmir.2024.02.004, PubMed 38429174